Malignant Pleural Effusion
A Malignant Pleural Effusion (MPE) is the build-up of fluid and cancer cells that collects between the chest wall and the lung. This can cause shortness of breath and/or chest discomfort. It is a fairly common complication in several different cancers. It forms when cells from either lung cancer or another type of cancer spread to the pleural space. These cancer cells increase the production of pleural fluid and cause decreased absorption of the fluid.
&nbsp;
<h2 dir="ltr">Malignant Pleural Effusion Epidemiology Segmentation</h2>
<ul>
<li dir="ltr" aria-level="1">
Incident Cases of MPE
</li>
<li dir="ltr" aria-level="1">
Tumor Type-specific Incident Cases of MPE
</li>
<li dir="ltr" aria-level="1">
Gender-specific Incident Cases of MPE
</li>
<li dir="ltr" aria-level="1">
Symptom-specific Incident Cases of MPE
</li>
</ul>
<h2 dir="ltr">Malignant Pleural Effusion Epidemiology</h2>
<ul>
<li dir="ltr" aria-level="1">
The total number of incident cases in the 7MM was estimated at approximately 480K.
</li>
<li dir="ltr" aria-level="1">
US - 35%
</li>
<li dir="ltr" aria-level="1">
EU4 and the UK - 51%
</li>
<li dir="ltr" aria-level="1">
Japan - 13%
</li>
<li dir="ltr" aria-level="1">
MPE imposes a significant burden on patients, severely impacting their quality of life. Physically, patients suffer from debilitating symptoms such as shortness of breath, chest pain, cough, and fatigue, which reduce mobility and independence.
</li>
<li dir="ltr" aria-level="1">
Psychologically, MPE leads to anxiety, depression, and fear of recurrence.
</li>
</ul>
<h3 dir="ltr">Tumor Type-specific Incident Cases of MPE in the 7MM</h3>
<ul>
<li dir="ltr" aria-level="1">
Lung - 41%
</li>
<li dir="ltr" aria-level="1">
Breast Cancer - 21%
</li>
<li dir="ltr" aria-level="1">
Lymphoma - 9%
</li>
<li dir="ltr" aria-level="1">
Others - 29%
</li>
<li dir="ltr" aria-level="1">
The United States reported an estimated 140K symptomatic incident cases of MPE, compared with nearly 35,000 asymptomatic cases, indicating that the majority of newly identified MPE patients presented with clinical symptoms at diagnosis rather than being detected incidentally alone.
</li>
</ul>
<h2 dir="ltr">Malignant Pleural Effusion Market</h2>
<ul>
<li dir="ltr" aria-level="1">
CAGR of 4.9% is predicted for the market during the study period (2022&ndash;2036).
</li>
<li dir="ltr" aria-level="1">
The market size in the 7MM in 2025 was estimated at approximately USD 2 billion.
</li>
<li dir="ltr" aria-level="1">
US - 52%
</li>
<li dir="ltr" aria-level="1">
EU4 and the UK - 38%
</li>
<li dir="ltr" aria-level="1">
Japan - 10%
</li>
<li dir="ltr" aria-level="1">
The MPE market currently lacks an FDA-approved drug, with no approved treatments available in Japan or Europe either.
</li>
<li dir="ltr" aria-level="1">
This absence highlights a critical unmet need, presenting opportunities for innovative therapies to address the growing demand for effective and standardized treatments across these major healthcare markets.
</li>
</ul>
<h2 dir="ltr">Malignant Pleural Effusion Market Drivers</h2>
<ul>
<li dir="ltr" aria-level="1">
Rising prevalence of cancer indications is significantly contributing to the increasing burden of MPE.
</li>
<li dir="ltr" aria-level="1">
Increasing global cancer burden and aging population are driving market expansion.
</li>
<li dir="ltr" aria-level="1">
Advancements in minimally invasive procedures are improving patient management and treatment accessibility.
</li>
<li dir="ltr" aria-level="1">
Ongoing clinical research activities are accelerating innovation and therapeutic development in MPE.
</li>
</ul>
<h2 dir="ltr">Malignant Pleural Effusion Market Barriers</h2>
<ul>
<li dir="ltr" aria-level="1">
The lack of a standardized care approach for intractable and refractory MPE contributes to poor prognosis and limited treatment outcomes.
</li>
<li dir="ltr" aria-level="1">
Limited epidemiological studies and prognostic markers continue to hinder optimized disease management.
</li>
<li dir="ltr" aria-level="1">
Risks of infection, catheter-related complications, and adverse effects associated with pleurodesis or systemic therapies may discourage certain interventions.
</li>
<li dir="ltr" aria-level="1">
The absence of approved targeted therapies remains a major clinical and commercial challenge.
</li>
</ul>
<h2 dir="ltr">Emerging Malignant Pleural Effusion Drugs</h2>
<ul>
<li dir="ltr" aria-level="1">
PTS500
</li>
<li dir="ltr" aria-level="1">
M701
</li>
<li dir="ltr" aria-level="1">
RSO-021
</li>
<li dir="ltr" aria-level="1">
And others
</li>
</ul>
<h2 dir="ltr">Key Malignant Pleural Effusion Companies</h2>
<ul>
<li dir="ltr" aria-level="1">
Gongwing Biopharm
</li>
<li dir="ltr" aria-level="1">
Wuhan YZY Biopharma
</li>
<li dir="ltr" aria-level="1">
RS Oncology
</li>
<li dir="ltr" aria-level="1">
And others
</li>
</ul>
&nbsp;

Malignant Pleural Effusion Market

Malignant Pleural Effusion Market infographics

Malignant Pleural Effusion Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape